drugs against erectile dysfunction do not play the role in the prevention of prostate cancer, the study shows -
Although some previous studies have shown that taking erectile dysfunction (ED) drugs can reduce the likelihood of developing prostate cancer, a new study published in the Journal of Urology® found that these drugs do not play a role in cancer prevention prostate.
ED is a common problem with a prevalence of 20% to 40% in the sixth decade of life and approaching 75% in the seventh decade. Drugs such as tadalafil, sildenafil, vardenafil and are inhibitors of phosphodiesterase type 5 (PDE-5) commonly used to treat erectile dysfunction. Since PDE-5's were introduced in 1998, their durability, safety and efficacy for the treatment of ED have been clearly demonstrated.
"The in vitro mouse studies have suggested that these drugs might have anticancer activity, but the evidence in humans is mixed," said principal investigator Stephen J. Freedland, MD, Division Urology, Department of surgery at the Institute of cancer Samuel Oschin complete at Cedars-Sinai in Los Angeles, CA. "Given the systematic use of PDE-5i and the possibility that these agents may have anticancer activity, we wanted to test the association between their use and the risk of developing prostate cancer."
using rEDUCE data, -Year four, test the effect of dutasteride daily to treat benign prostatic hyperplasia risk of prostate cancer in men multicenter study, the authors analyzed whether ED drug use by over 6,500 patients may have an impact on cancer risk of overall prostate and quality of disease (Gleason 2-6 and 7-10). All participants in the REDUCE trial were undergo biopsies two and four years after registration, which facilitated the evaluation of cancer uniform throughout the group. in this way, the basic science linking PDE-5i and anticancer activity could be explored .
Among the 6,501 men in the study 364 (5.6%) used PDE-5i out. During the study, prostate cancer was diagnosed in 71 of the men (19.5%) compared to 1391 of 6137 (22.7%) of men who do not take PDE-5i, which was not significantly different. An analysis of prostate cancer quality also showed no correlation between PDE-5i use and low or high grade cancer. Because the use of PDE-5i was significantly higher among North American men, the authors sought a regional effect. They found a correlation between the use of ED and under diagnosis of prostate cancer in North American men, but this did not reach statistical significance.
"Future studies with more follow-up and larger populations are needed to determine the association between PDE-5i and prostate cancer," said Juzar Jamnagerwalla, MD, urology resident at Cedars-Sinai and first author of the study.
EmoticonEmoticon